Thermo Fisher Scientific (TMO) Projected to Post Earnings on Thursday

Thermo Fisher Scientific (NYSE:TMO) is expected to release its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect Thermo Fisher Scientific to post earnings of $6.44 per share and revenue of $11.9519 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the firm posted $5.28 earnings per share. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Up 2.8%

Shares of NYSE:TMO opened at $636.26 on Thursday. The firm has a 50 day simple moving average of $588.78 and a 200 day simple moving average of $528.67. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $637.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The company has a market cap of $239.05 billion, a PE ratio of 36.76, a price-to-earnings-growth ratio of 4.07 and a beta of 0.91.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were issued a $0.43 dividend. The ex-dividend date was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. The Goldman Sachs Group began coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price target on the stock. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. Evercore ISI reissued an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. TD Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Insider Activity

In related news, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the transaction, the executive vice president directly owned 18,731 shares in the company, valued at $11,238,600. The trade was a 36.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 89.1% in the 2nd quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock valued at $720,576,000 after acquiring an additional 825,649 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $207,369,000. Invesco Ltd. raised its position in shares of Thermo Fisher Scientific by 22.8% in the third quarter. Invesco Ltd. now owns 1,915,286 shares of the medical research company’s stock valued at $928,952,000 after purchasing an additional 355,659 shares during the period. Caisse de depot et placement du Quebec lifted its stake in shares of Thermo Fisher Scientific by 12,110.2% in the third quarter. Caisse de depot et placement du Quebec now owns 343,838 shares of the medical research company’s stock worth $166,768,000 after buying an additional 341,022 shares during the last quarter. Finally, Freestone Grove Partners LP bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $82,514,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.